Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $0.002 | N/A |
Market Cap | $4.88M | N/A |
Shares Outstanding | 2.44B | N/A |
Employees | 0 | N/A |